Table 2.
Baseline demographics and clinical characteristics of the patient population.
| Parameters | Baseline demographics and clinical characteristics |
|---|---|
| No. of subjects | 381 |
| Sex (M/F) | 225/156 (59.1%/40.9%) |
| Age (mean) (year) | 60.61 ± 9.40 |
| RISS Stage | |
| Stage I | 38 (10.0%) |
| Stage II | 236 (61.9%) |
| Stage III | 107 (28.1%) |
| Type | |
| IgA-λ | 31 (8.1%) |
| IgD-λ | 35 (9.2%) |
| IgG- | 123 (32.3%) |
| λ | 68 (17.8%) |
| IgA-κ | 37 (9.7%) |
| IgG-κ | 58 (15.2%) |
| κ | 29 (7.6%) |
| Therapeutic response | |
| CR | 131 (34.4%) |
| sCR | 85 (22.3%) |
| PR | 74 (19.4%) |
| VGPR | 51 (13.4%) |
| SD | 23 (6.0%) |
| PD | 17 (4.5%) |
CR, complete response; PD, progressive disease; PR, partial response; RISS, Revised International Staging System; sCR, strict complete response; SD, stable disease; VGPR, very good partial response.